JP2015524823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524823A5 JP2015524823A5 JP2015525617A JP2015525617A JP2015524823A5 JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5 JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antithrombin
- recombinant antithrombin
- administered
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004019 antithrombin Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 229940089003 atryn Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679345P | 2012-08-03 | 2012-08-03 | |
| US61/679,345 | 2012-08-03 | ||
| PCT/US2013/053365 WO2014022748A1 (en) | 2012-08-03 | 2013-08-02 | The use of antithrombin in extracorporeal membrane oxygenation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524823A JP2015524823A (ja) | 2015-08-27 |
| JP2015524823A5 true JP2015524823A5 (https=) | 2016-09-23 |
| JP6389172B2 JP6389172B2 (ja) | 2018-09-12 |
Family
ID=50028554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525617A Expired - Fee Related JP6389172B2 (ja) | 2012-08-03 | 2013-08-02 | 体外式膜型人工肺におけるアンチトロンビンの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9511087B2 (https=) |
| EP (1) | EP2879697A4 (https=) |
| JP (1) | JP6389172B2 (https=) |
| KR (1) | KR20150039201A (https=) |
| CN (1) | CN104884080A (https=) |
| AR (1) | AR091977A1 (https=) |
| AU (1) | AU2013296240B2 (https=) |
| BR (1) | BR112015002321A2 (https=) |
| CA (1) | CA2879763C (https=) |
| IL (1) | IL236776A0 (https=) |
| MX (1) | MX2015001508A (https=) |
| TW (1) | TW201425332A (https=) |
| WO (1) | WO2014022748A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811526T3 (es) | 2010-12-30 | 2021-03-12 | Lab Francais Du Fractionnement | Glicoles como agentes de inactivación de patógenos |
| EP2879697A4 (en) | 2012-08-03 | 2016-01-20 | Lfb Usa Inc | USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3016729B1 (fr) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Matrice de chromatographie d'affinité |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| DE4028800A1 (de) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
| DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5801063A (en) | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
| US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| CA2281949A1 (en) | 1997-02-25 | 1998-08-27 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
| US20060264357A1 (en) * | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| DE10159556A1 (de) | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| CA2479968A1 (en) | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
| EP1776108A1 (en) | 2004-06-23 | 2007-04-25 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20090148458A1 (en) | 2005-06-23 | 2009-06-11 | The University Of British Columbia | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
| WO2007014244A2 (en) | 2005-07-25 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
| KR20140133958A (ko) | 2005-10-21 | 2014-11-20 | 엘에프비 유에스에이, 인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법 |
| US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
| US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| US8173860B2 (en) | 2006-04-21 | 2012-05-08 | Gtc Biotherapeutics, Inc. | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion |
| WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
| US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
| EP2729164A4 (en) | 2011-07-07 | 2015-05-06 | Lfb Usa Inc | FORMULATIONS STABILIZING PROTEINS |
| TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| EP2879697A4 (en) | 2012-08-03 | 2016-01-20 | Lfb Usa Inc | USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE |
-
2013
- 2013-08-02 EP EP13825397.6A patent/EP2879697A4/en not_active Withdrawn
- 2013-08-02 AU AU2013296240A patent/AU2013296240B2/en not_active Ceased
- 2013-08-02 AR ARP130102756A patent/AR091977A1/es unknown
- 2013-08-02 US US14/239,943 patent/US9511087B2/en not_active Expired - Fee Related
- 2013-08-02 CN CN201380041286.1A patent/CN104884080A/zh active Pending
- 2013-08-02 CA CA2879763A patent/CA2879763C/en active Active
- 2013-08-02 WO PCT/US2013/053365 patent/WO2014022748A1/en not_active Ceased
- 2013-08-02 TW TW102127828A patent/TW201425332A/zh unknown
- 2013-08-02 BR BR112015002321A patent/BR112015002321A2/pt not_active IP Right Cessation
- 2013-08-02 KR KR1020157002667A patent/KR20150039201A/ko not_active Ceased
- 2013-08-02 MX MX2015001508A patent/MX2015001508A/es unknown
- 2013-08-02 JP JP2015525617A patent/JP6389172B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-18 IL IL236776A patent/IL236776A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524823A5 (https=) | ||
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| JP2013509429A5 (https=) | ||
| JP2013507439A5 (https=) | ||
| MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| JP2015502389A5 (https=) | ||
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| FI3978074T3 (fi) | Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi | |
| HRP20200009T1 (hr) | Angiotenzin ii u kombinaciji za liječenje hipotenzije | |
| FI3630164T3 (fi) | Dulaglutidi kroonisen munuaissairauden hoitoon | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| JP2012526099A5 (https=) | ||
| CA2525202A1 (en) | Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza | |
| CN102488697A (zh) | 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用 | |
| FR2961695B1 (fr) | Utilisation de composes dans le traitement ou la prevention de troubles cutanes | |
| JP2019507134A5 (https=) | ||
| JP2017508455A5 (https=) | ||
| JP2010538054A5 (https=) | ||
| WO2012040164A3 (en) | Tlr5 ligands, therapeutic methods, and compositions related thereto | |
| JP2016510040A5 (https=) |